Recent Updates
Recently added Catalysts
VOR Positive Sentiment

Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference

Monday, February 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Vor Bio will participate in the 46th Annual TD Cowen Health Care Conference in Boston, scheduled for March 2, 2026. The company will present its advancements in the treatment of autoimmune diseases and host one-on-one investor meetings. A live webcast of the presentation will be available for 90 days on their website.
Price reaction · baseline $13.55 (2026-02-20 close) · hit pre-market · clean, no other VOR news in the window
day 0 close
+13.8%
day 1
+13.3%
day 3 · peak
+17.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Vor Bio is actively participating in a major healthcare conference.
  • The company is advancing its innovative treatment for autoimmune diseases.
  • The presentation will be accessible via a live webcast.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+442%
120-day peak, hindsight
Typical move
18.8%
average across 6 past catalysts
Cash runway
~55 mo
Minimal dilution risk
Lead asset
Telitacicept
Phase 3 · Primary Sjogren's Disease

Full Press Release Details

BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting and hosting 1x1 investor meetings at the 46th Annual TD Cowen Health Care Conference in Boston, MA.
Presentation: Monday, March 2, 2026 at 9:50am – 10:20 am ETLocation: Regis
A live webcast and archived replay of the presentation will be remain available for a period of 90 days on the Company’s website at:https://ir.vorbio.com/events-presentations/
About Vor BioVor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visitwww.vorbio.com.

Media & Investor Contacts:Carl Mauchcmauch@vorbio.com

Frequently Asked Questions

When will Vor Bio present at the conference?

Vor Bio will present on March 2, 2026, from 9:50 am to 10:20 am ET.

Where is the TD Cowen Health Care Conference held?

The conference will take place in Boston, MA.

What is Vor Bio's focus area?

Vor Bio focuses on transforming the treatment of autoimmune diseases.

How can I access the presentation?

The presentation will be available via a live webcast for 90 days.

ShareAdd on Google
Tags: VOR Viatris Investor Conferences Healthcare Vor Bio TD Cowen Conference autoimmune diseases telitacicept biotechnology
Last updated: Feb 23, 2026

Biotech snapshot

Cash runway
$466M liquidity · $8M/mo burn
~55 mo
Minimal dilution risk
Lead asset
TelitaciceptPhase 3
Primary Sjogren's Disease →

Catalyst track record

+442%
best trade around VOR's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for VOR.

See every catalyst's timing & PoA →